Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer-Reference-Cited by-同舟云学术

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

Published:2012-07-01 Issue:8 Volume:44 Page:852-860
ISSN:1061-4036
Container-title:Nature Genetics
language:en
Short-container-title:Nat Genet

Author:

Zhang Zhenfeng,Lee Jae Cheol,Lin Luping,Olivas Victor,Au Valerie,LaFramboise Thomas,Abdel-Rahman Mohamed,Wang Xiaoqi,Levine Alan D,Rho Jin Kyung,Choi Yun Jung,Choi Chang-Min,Kim Sang-We,Jang Se Jin,Park Young Soo,Kim Woo Sung,Lee Dae Ho,Lee Jung-Shin,Miller Vincent A,Arcila Maria,Ladanyi Marc,Moonsamy Philicia,Sawyers Charles,Boggon Titus J,Ma Patrick C,Costa Carlota,Taron Miquel,Rosell Rafael,Halmos Balazs,Bivona Trever G

Publisher

Springer Science and Business Media LLC

Subject

Genetics

Link

http://www.nature.com/articles/ng.2330.pdf

Reference29 articles.

1. Paez, J.G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004).

2. Pao, W. et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 101, 13306–13311 (2004).

3. Lynch, T.J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004).

4. Sordella, R., Bell, D.W., Haber, D.A. & Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163–1167 (2004).

5. Jänne, P.A., Gray, N. & Settleman, J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat. Rev. Drug Discov. 8, 709–723 (2009).

Cited by 1018 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer drug-tolerant persister cells: from biological questions to clinical opportunities;Nature Reviews Cancer;2024-09-02

2. Cancer plasticity in therapy resistance: Mechanisms and novel strategies;Drug Resistance Updates;2024-09

3. AXL inhibition prevents RPA2/CHK1-mediated homologous recombination to increase PARP inhibitor sensitivity in hepatocellular carcinoma;Heliyon;2024-09

4. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24

5. PrPC controls epithelial-to-mesenchymal transition in EGFR-mutated NSCLC: implications for TKI resistance and patient follow-up;Oncogene;2024-08-15